GlassScriptPhysician profile
John A Garrison
NPI 1902284870
$14,033.13
in general payments reported to CMS, 2019-2025
34 companies · $3,295 in 2025
The $3,295 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $302 · 2021: $929 · 2022: $5,493 · 2023: $2,134 · 2024: $1,528 · 2025: $3,295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,462 · Travel and Lodging: $2,178 · Education: $317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,462.15 |
| Travel and Lodging | $2,177.67 |
| Education | $316.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $3,590.89 | 2021-2022 | |
| Kerecis Limited | $1,285.02 | 2024-2025 | Kerecis Surgiclose, Kerecis Graftguide, Kerecis Omega3 Marigen |
| Organogenesis INC. | $1,063.04 | 2020-2024 | Puraply, Puraply Wound Matrix, Puraply Am |
| Bard Peripheral Vascular, INC. | $1,043.06 | 2023 | Venclose Maven Catheter |
| Smith+Nephew, INC. | $1,009.42 | 2020-2024 | Grafix, Stravix, Grafix Pl |
| Solventum Corporation | $991.27 | 2025 | Activ.A.C., Bair Hugger, V.A.C. Veraflo |
| Abbvie INC. | $962.02 | 2021-2025 | |
| Mimedx Group, INC. | $742.38 | 2024-2025 | |
| Kci USA, INC. | $548.99 | 2019-2023 | V.A.C. Veraflo |
| Acera Surgical, INC. | $466.79 | 2021-2023 | Restrata Wound Matrix |
| Paratek Pharmaceuticals, INC. | $266.89 | 2021-2025 | Nuzyra |
| Tactile Systems Technology INC | $224.41 | 2021-2023 | Flexitouch Plus, Entre Plus |
| Avita Medical Americas, LLC | $174.48 | 2024 | |
| Inari Medical, INC. | $170.83 | 2022 | |
| Boston Scientific Corporation | $166.41 | 2024 | Varithena Administration Pack |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $155.59 | 2023 | Hawkone |
| Sk Life Science, INC. | $152.45 | 2025 | |
| Neurocrine Biosciences, INC. | $152.01 | 2024 | |
| Lucid Diagnostics INC. | $146.04 | 2022 | |
| Allergan, INC. | $132.85 | 2019-2020 | |
| Ets Wound Care LLC | $102.85 | 2023 | |
| Melinta Therapeutics, LLC | $95.95 | 2024 | Kimyrsa |
| Tetraphase Pharmaceuticals, INC. | $92.59 | 2020 | |
| Cook Medical LLC | $59.52 | 2025 | Zilver Ptx |
| Janssen Biotech, INC. | $51.63 | 2019 | |
| Integra Lifesciences Corporation | $30.24 | 2021-2023 | Tcc-Ez |
| Amgen INC. | $26.73 | 2024 | Otezla, Repatha |
| La Jolla Pharmaceutical Company | $26.33 | 2024 | Xerava |
| Lifenet Health | $20.50 | 2025 | Theragenesis Wound Matrix |
| Bsn Medical INC | $19.59 | 2022 | |
| Convatec INC. | $16.09 | 2020 | |
| Next Science LLC | $15.91 | 2023 | Surgx, Blastx, Xperience |
| Pfizer INC. | $15.49 | 2021 | |
| Medline Industries LP | $14.87 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Garrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.